A Phase 2 interventional study of emollient (Cetaphil cream) in Atopic Dermatitis, sponsored by Oregon Health and Science University. Completed at 1 site in United States. Open to participants aged Up to 1 Month. Per ClinicalTrials.gov, last updated 2017-07-11.
Sponsored by Oregon Health and Science University · Phase 2, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 639 studies in Dermatitis, Atopic with a site in United States — 78 open to participants now, 117 under way, 18 of them phase 3. Dermatitis, Atopic · United States.
Among the 639 studies in Dermatitis, Atopic with a site in United States, this one is the 447th largest by enrollment of the 544 interventional ones that give a count, is one of 9 that started in 2006, is one of 202 in phase 2, and was the 54th registered.
1,596 studies on the registry are indexed under Dermatitis, Atopic; 289 are open to participants now.
Browse Dermatitis, Atopic studies →78 of the 639 studies in Dermatitis, Atopic with a site in United States are open now. Recruiting first, the newest first:
National Institute of Allergy and Infectious Diseases (NIAID) · Sites in United States
Ages 12–120
Weill Medical College of Cornell University · Sites in United States
Ages 13–17
Arcutis Biotherapeutics, Inc. · Sites in United States
Ages 6+
Triveni Bio · Sites in United States, Canada, Ukraine
Ages 18–75
Pfizer · Sites in United States, Canada, Japan and 1 more country
Ages 12+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 195 Dermatitis, Atopic studies recruiting now, 84 (43%) set no upper age limit and 95 (49%) stop at 75 or younger; 94 take children under 18; 52 take healthy volunteers.
This study: Up to 1 Month · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
639 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 97 · Phase 2 221 · Phase 3 107 · Phase 4 70
First in 1996; this study’s year is marked. 9 started in 2006.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 22 is below the median of 82 across 1,249 interventional studies indexed under Dermatitis, Atopic.
Median enrollment 96 across the 544 interventional studies, 155 across the 94 observational. Of the 491 that completed or were terminated, 265 (54%) have results posted.
This tab as a report to print or save as PDF → With an account.
429 of 639 have an industry lead sponsor. The 10 most frequent:
Oregon Health and Science University is the lead sponsor of 697 studies on the registry; 129 are open to participants now.
Of its 53 completed or terminated interventional studies of FDA-regulated products, 39 (74%) have results posted.
Oregon Health and Science University has 7 studies filed under Dermatitis, Atopic — fewer than ten, so there is no comparison to draw.
42 of the studies in Dermatitis, Atopic with a site in United States that are under way reach primary completion within a year, 4 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06389136Phase 3AbbVieA Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab | 2026-11 |
| NCT07355075Phase 3Turn TherapeuticsA Double-Blind, Randomized, Vehicle-Controlled Phase 2 Study to Assess the Efficacy and Safety of GX-03 in Adult Subjects With Moderate to Severe Atopic Dermatitis (Eczema) | 2027-01-20 |
| NCT07265479Phase 3Organon and CoA Study to Investigate Safety and Efficacy of Tapinarof Cream, 1% in Participants Ages 3 Months to < 24 Months With Atopic Dermatitis | 2027-08 |
| NCT06241118Phase 3SanofiA Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab on Background Topical Corticosteroids Therapy in Participants Aged 12 Years and Older With Moderate-to-severe AD Who Have Had an Inadequate Response to Prior Biologic Therapy or an Oral JAK Inhibitor | 2027-09-30 |
| NCT06395948Apogee Therapeutics, Inc.A Study Evaluating APG777 in Atopic Dermatitis | 2026-11 |
Add all 42 to your calendar (.ics) → With an account.
Among the 639 studies in Dermatitis, Atopic with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to determine whether early use of a bland emollient in newborns, prior to the clinical signs of skin disease, will delay the onset or prevent the development of atopic dermatitis.
All neonates will be treated with Cetaphil cream starting within 1 week of birth. All neonates enrolled will have an increased risk of developing atopic dermatitis because they have a family history of either asthma, hay fever, or atopic dermatitis. These neonates will then be followed for 2 years for the signs and symptoms of atopic dermatitis.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Skin barrier protection from birth
Drug: emollient (Cetaphil cream)
Cetaphil cream applied daily from birth
Incidence of Skin Irritation
Time frame: 1 and 2 year time points
Incidence of Skin Infection
Time frame: 1 and 2 year timepoints
Compliance With Protocol
Time frame: over two years
Development of Eczema
Time frame: 1 and 2 year time points
| Milestone | Emollient |
|---|---|
| Started | 22 |
| Completed | 20 |
| Not completed | 2 |
| Participants | Emollient |
|---|---|
| Incidence of Skin Irritation | 0 |
| Participants | Emollient |
|---|---|
| Incidence of Skin Infection | 0 |
| participants | Emollient |
|---|---|
| Compliance With Protocol | 20 |
| Participants | Emollient |
|---|---|
| Development of Eczema | 5 |
Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Emollient | — | 0/22 (0%) | 0/22 (0%) |
| Age, Categorical(Participants) | Emollient |
|---|---|
| <=18 years | 22 |
| Between 18 and 65 years | 0 |
| >=65 years | 0 |
| Sex/Gender, Customized(participants) | Emollient |
|---|---|
| gender/sex was not recorded | 22 |
| Race/Ethnicity, Customized(Participants) | Emollient |
|---|---|
| non-Hispanic Caucasian | 16 |
| Hispanic Caucasian | 2 |
| Asian | 2 |
| African American | 2 |
| Region of Enrollment(participants) | Emollient |
|---|---|
| United States | 22 |
The record gives a start of Nov 2006, a primary completion of Nov 2008 and a completion of Nov 2009. It does not say whether these dates are actual or estimated.
Results were first posted in Jul 2017, 8 years 8 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Cetyl alcohol, propylene glycol, sodium lauryl sulfate non-lipid cleansing lotion
Oregon Health and Science University →